NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central ...
Huntsman Mental Health Institute is pleased to celebrate Rana Jawish, MD, and Ben Lewis, MD, who were named recipients of the 2024 New Investigator Award from the American Society of Clinical ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. A machine learning model processed data from more than ...
MUNICH, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- Ketabon GmbH (“Ketabon” or “the Company”), a joint venture between HMNC Brain Health and Develco Pharma, announced today the Company will present ...
LAS CRUCES - The clinical psychopharmacology program at New Mexico State University is a unique program with students from across North America and the world, attracting practicing psychologists ...
– Convergent clinical and preclinical evidence supports the mechanistic link between ALTO-300 and the biomarker, a measure of greater EEG irregularity, being used for patient selection – – Completed ...
Posters Highlight New Insights into Social Anxiety Disorder and the Novel Mechanism of Action of Itruvone to Treat Major Depressive Disorder Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical ...
SAN DIEGO, May 28, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of data from the Phase 2 study of NBI-1117568 in adults with schizophrenia, which ...
Alto Neuroscience Presents Data at the 2025 American Society of Clinical Psychopharmacology Annual Meeting Reinforcing Safety and Tolerability Profile for ALTO-300 in Major Depressive Disorder – ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback